IPM Take
Alzheimer’s drug development is tired of amyloid alone. That does not mean every new mechanism gets a free pass.
Sanofi’s SAR448851 moves the argument toward microglia and TREM2, a pathway tied to genetic risk, immune activity and the brain’s response to amyloid and tau. It is a serious idea. It is also an idea entering a field where elegant biology has repeatedly failed to become patient benefit.
The lesson is not to be cynical. The lesson is to be harder on the evidence before the story becomes bigger than the data.
Executive Summary
At the 2026 Alzheimer’s Association International Conference, investigators presented the design of TREMHANCE, a Phase II study of SAR448851, Sanofi’s investigational oral small-molecule TREM2 agonist, in early Alzheimer’s disease.
The trial is expected to enrol people aged 55 to 85 years with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, confirmed amyloid pathology, CDR 0.5 to 1.0 and MMSE of at least 20. Participants will be randomised to SAR448851 or placebo for 48 weeks, followed by an open-label extension.
The planned primary endpoint is change in plasma p-tau217 at week 48. Secondary endpoints include additional fluid biomarkers, neuroimaging and safety measures.
Phase I data reportedly showed favourable safety, high central nervous system penetration and dose-dependent target engagement, including up to 50% reduction in CSF soluble TREM2. These are early data. TREMHANCE has not yet shown clinical efficacy.
Why it matters
- Patients / advocates: A new Alzheimer’s mechanism should not be mistaken for a treatment result. Families need proof of benefit, not only proof that the biology moves.
- Clinicians: TREM2 activation may become an important approach, but clinical value will depend on cognition, function and safety, not target engagement alone.
- Researchers / academia: The programme tests whether oral CNS-penetrant TREM2 agonism can avoid the problems seen with earlier TREM2 approaches.
- Regulators: A biomarker-primary Phase II design can guide development, but it cannot settle whether the intervention changes the disease.
Alzheimer’s has become a graveyard of mechanisms that made sense.
Amyloid made sense. Tau made sense. Neuroinflammation makes sense. TREM2 makes sense. The problem is not the biological logic. The problem is the long distance between changing a pathway and helping a person stay themselves for longer.
SAR448851 is interesting because it targets microglia, the immune cells that help shape the brain’s response to Alzheimer’s pathology. The rationale is not decorative. Loss-of-function TREM2 variants increase Alzheimer’s risk, and microglial activity sits close to the disease process.
But this pathway already carries warning signs.
A previous TREM2 agonist antibody, AL002, showed target engagement but failed to deliver CDR-SB benefit in early Alzheimer’s disease and raised safety concerns, including ARIA-like MRI findings. Sanofi’s oral small-molecule approach may behave differently. It may penetrate the CNS more predictably. It may offer a better development path.
Or it may remind the field that target engagement is not enough.
That is why TREMHANCE matters as a test, not as a claim. A p-tau217 primary endpoint can help show whether the drug moves downstream Alzheimer’s biology. It cannot, on its own, tell families whether memory, independence, work, social life or caregiver burden will change.
The field needs mechanisms beyond amyloid. But it also needs discipline beyond enthusiasm.
If microglial medicine is going to matter, it must eventually prove that it does more than make biomarkers behave. It has to change what Alzheimer’s does to people.
